|
1
|
Rahman F, Kwan GF and Benjamin EJ: Global
epidemiology of atrial fibrillation. Nat Rev Cardiol. 11:639–654.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nattel S and Dobrev D:
Electrophysiological and molecular mechanisms of paroxysmal atrial
fibrillation. Nat Rev Cardiol. 13:575–590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wakili R, Voigt N, Kääb S, Dobrev D and
Nattel S: Recent advances in the molecular pathophysiology of
atrial fibrillation. J Clin Invest. 121:2955–2968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bikou O, Thomas D, Trappe K, Lugenbiel P,
Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA and Bauer
A: Connexin 43 gene therapy prevents persistent atrial fibrillation
in a porcine model. Cardiovasc Res. 92:218–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Segretain D and Falk MM: Regulation of
connexin biosynthesis, assembly, gap junction formation, and
removal. Biochim Biophys Acta. 1662:3–21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davis LM, Kanter HL, Beyer EC and Saffitz
JE: Distinct gap junction protein phenotypes in cardiac tissues
with disparate conduction properties. J Am Coll Cardiol.
24:1124–1132. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Igarashi T, Finet JE, Takeuchi A, Fujino
Y, Strom M, Greener ID, Rosenbaum DS and Donahue JK: Connexin gene
transfer preserves conduction velocity and prevents atrial
fibrillation. Circulation. 125:216–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van Rooij E and Olson EN: MicroRNA
therapeutics for cardiovascular disease: Opportunities and
obstacles. Nat Rev Drug Discov. 11:860–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo X, Yang B and Nattel S: MicroRNAs and
atrial fibrillation: Mechanisms and translational potential. Nat
Rev Cardiol. 12:80–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nattel S and Harada M: Atrial remodeling
and atrial fibrillation: Recent advances and translational
perspectives. J Am Coll Cardiol. 63:2335–2345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishi H, Sakaguchi T, Miyagawa S,
Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T and Sawa Y:
Impact of microRNA expression in human atrial tissue in patients
with atrial fibrillation undergoing cardiac surgery. PLoS One.
8:e733972013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Radtke A, Hanke T, Yan J, Godau B, Cordes
J, Nigam V, Sievers HH and Mohamed SA: MicroRNA 208 in atrial
fibrillation. J Clin Exp Cardiol. 5:3252014.
|
|
13
|
January CT, Wann LS, Alpert JS, Calkins H,
Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD,
Field ME, et al: 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: A report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol.
64:e1–e76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
16
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rehmsmeier M, Steffen P, Hochsmann M and
Giegerich R: Fast and effective prediction of microRNA/target
duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Davidson MM, Nesti C, Palenzuela L, Walker
WF, Hernandez E, Protas L, Hirano M and Isaac ND: Novel cell lines
derived from adult human ventricular cardiomyocytes. J Mol Cell
Cardiol. 39:133–147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Firouzi M, Ramanna H, Kok B, Jongsma HJ,
Koeleman BP, Doevendans PA, Groenewegen WA and Hauer RN:
Association of human connexin40 gene polymorphisms with atrial
vulnerability as a risk factor for idiopathic atrial fibrillation.
Circ Res. 95:e29–e33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gollob MH, Jones DL, Krahn AD, Danis L,
Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, et al:
Somatic mutations in the connexin 40 gene (GJA5) in atrial
fibrillation. N Engl J Med. 354:2677–2688. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Juang JM, Chern YR, Tsai CT, Chiang FT,
Lin JL, Hwang JJ, Hsu KL, Tseng CD, Tseng YZ and Lai LP: The
association of human connexin 40 genetic polymorphisms with atrial
fibrillation. Int J Cardiol. 116:107–112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kostin S, Klein G, Szalay Z, Hein S, Bauer
EP and Schaper J: Structural correlate of atrial fibrillation in
human patients. Cardiovasc Res. 54:361–379. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rucker-Martin C, Milliez P, Tan S, Decrouy
X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I,
Segretain D and Hatem SN: Chronic hemodynamic overload of the atria
is an important factor for gap junction remodeling in human and rat
hearts. Cardiovasc Res. 72:69–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiao P, Gao C, Fan J, Du H, Long Y and Yin
Y: Blockade of angiotensin II improves hyperthyroid induced
abnormal atrial electrophysiological properties. Regul Pept.
169:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hagendorff A, Schumacher B, Kirchhoff S,
Lüderitz B and Willecke K: Conduction disturbances and increased
atrial vulnerability in Connexin40-deficient mice analyzed by
transesophageal stimulation. Circulation. 99:1508–1515. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oliveira-Carvalho V, Carvalho VO and
Bocchi EA: The emerging role of miR-208a in the heart. DNA Cell
Biol. 32:8–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Rooij E, Sutherland LB, Qi X,
Richardson JA, Hill J and Olson EN: Control of stress-dependent
cardiac growth and gene expression by a microRNA. Science.
316:575–579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Satoh M, Minami Y, Takahashi Y, Tabuchi T
and Nakamura M: Expression of microRNA-208 is associated with
adverse clinical outcomes in human dilated cardiomyopathy. J Card
Fail. 16:404–410. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paulin R, Sutendra G, Gurtu V, Dromparis
P, Haromy A, Provencher S, Bonnet S and Michelakis ED: A
miR-208-Mef2 axis drives the decompensation of right ventricular
function in pulmonary hypertension. Circ Res. 116:56–69. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Callis TE, Pandya K, Seok HY, Tang RH,
Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, et al:
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction
in mice. J Clin Invest. 119:2772–2786. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Linhares VL, Almeida NA, Menezes DC,
Elliott DA, Lai D, Beyer EC, de Carvalho Campos AC and Costa MW:
Transcriptional regulation of the murine Connexin40 promoter by
cardiac factors Nkx2-5, GATA4 and Tbx5. Cardiovasc Res. 64:402–411.
2004. View Article : Google Scholar : PubMed/NCBI
|
